Pharmaceuticals

Daiichi Sankyo and Merck Initiate Phase 3 Study to Evaluate Safety and Efficacy of Ifinatamab Deruxtecan in Patients with Recurrent Small Cell Lung Cancer

bexib
By bexib 0 Min Read

IDeate-Lung02 will compare ifinatamab deruxtecan to physician’s choice of chemotherapy in patients with recurrent small cell lung cancer.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Occupy Bitcoin: Bitcoin is not just libertarian
Next Article Asia FX firms bet on rate cut, yen hits 5-month high on hawkish BoJ stance Investing.com – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Is it a wise choice to join?
Insurance
Warwickshire’s biggest secret revealed as new speakeasy bar opens
Hospitality & Tourism
Processing superalloys while cooling them
Manufacturing
Carlowley Castle announces new venture redefining luxury hospitality, opening doors to Scotland’s luxury estates
Hospitality & Tourism